InVitae Corp (NYSE:NVTA) insider Katherine Stueland sold 1,000 shares of the company’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $25.23, for a total value of $25,230.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

  • On Friday, March 15th, Katherine Stueland sold 1,000 shares of InVitae stock. The shares were sold at an average price of $23.49, for a total value of $23,490.00.
  • On Wednesday, February 27th, Katherine Stueland sold 1,000 shares of InVitae stock. The stock was sold at an average price of $19.61, for a total value of $19,610.00.

NVTA traded down $2.17 during midday trading on Wednesday, hitting $22.57. 2,766,380 shares of the company were exchanged, compared to its average volume of 1,756,368. The company has a market capitalization of $1.90 billion, a P/E ratio of -11.63 and a beta of 2.25. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.56 and a current ratio of 4.56. InVitae Corp has a 1-year low of $5.31 and a 1-year high of $26.77.

InVitae (NYSE:NVTA) last announced its quarterly earnings results on Tuesday, February 19th. The medical research company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.02. InVitae had a negative return on equity of 88.93% and a negative net margin of 87.58%. The company had revenue of $45.36 million for the quarter, compared to the consensus estimate of $40.87 million. Analysts forecast that InVitae Corp will post -1.81 EPS for the current year.

Large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can grew its position in shares of InVitae by 173.1% during the 4th quarter. Great West Life Assurance Co. Can now owns 7,920 shares of the medical research company’s stock valued at $84,000 after acquiring an additional 5,020 shares during the period. Morgan Stanley grew its position in shares of InVitae by 8.5% during the 3rd quarter. Morgan Stanley now owns 152,712 shares of the medical research company’s stock valued at $2,555,000 after acquiring an additional 11,957 shares during the period. MetLife Investment Advisors LLC grew its position in shares of InVitae by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 48,933 shares of the medical research company’s stock valued at $819,000 after acquiring an additional 17,395 shares during the period. Meeder Asset Management Inc. grew its position in shares of InVitae by 183.3% during the 4th quarter. Meeder Asset Management Inc. now owns 15,640 shares of the medical research company’s stock valued at $174,000 after acquiring an additional 10,119 shares during the period. Finally, Boston Advisors LLC grew its position in shares of InVitae by 11.7% during the 4th quarter. Boston Advisors LLC now owns 54,375 shares of the medical research company’s stock valued at $601,000 after acquiring an additional 5,700 shares during the period. Hedge funds and other institutional investors own 74.69% of the company’s stock.

NVTA has been the topic of several analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $20.00 price target on shares of InVitae in a research report on Wednesday, February 20th. They noted that the move was a valuation call. Benchmark increased their price target on InVitae from $17.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, February 20th. Chardan Capital initiated coverage on InVitae in a research report on Monday, March 4th. They set a “buy” rating and a $29.00 price target on the stock. Oppenheimer increased their price target on InVitae from $21.00 to $30.00 and gave the stock an “outperform” rating in a research report on Monday, April 8th. Finally, CIBC initiated coverage on InVitae in a research report on Wednesday, December 19th. They set an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $22.80.

TRADEMARK VIOLATION NOTICE: “InVitae Corp (NVTA) Insider Sells $25,230.00 in Stock” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://theolympiareport.com/2019/04/17/invitae-corp-nvta-insider-sells-25230-00-in-stock.html.

About InVitae

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Featured Article: Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.